WO2002000228A1 - Composition ophtalmique contenant de l'oxygene - Google Patents
Composition ophtalmique contenant de l'oxygene Download PDFInfo
- Publication number
- WO2002000228A1 WO2002000228A1 PCT/JP2001/005542 JP0105542W WO0200228A1 WO 2002000228 A1 WO2002000228 A1 WO 2002000228A1 JP 0105542 W JP0105542 W JP 0105542W WO 0200228 A1 WO0200228 A1 WO 0200228A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxygen
- container
- ophthalmic composition
- hemoglobin
- dissolved
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- the present invention relates to an ophthalmic composition having an increased oxygen content. More specifically, the present invention relates to a composition for preventing or treating an eye disease associated with hypoxia.
- corneal conjunctiva becomes hypoxic, disorders such as hyperemia and corneal edema (corneal swelling) occur.
- corneal vascular infiltration, punctate keratopathy, corneal neovascularization, and corneal epithelial erosion Acute corneal epithelial edema, corneal infiltration, or various corneal endothelial disorders can occur.
- a stable supply of oxygen is essential for the normal maintenance of the eyes, especially the cornea.
- the surface of the cornea is covered by a tear film (tear film).
- the amount of dissolved oxygen in tears can be expressed as the oxygen partial pressure.
- the oxygen partial pressure of tears is reported to be approximately 150 mmHg when the eyelid is open and 55 mmHg when the eyelid is closed (Japanese Contact Lenses) Journal 29: 23-30, 1987).
- the cornea takes in dissolved oxygen in the tears according to the oxygen partial pressure of the tears. As the amount of tears decreases, the total amount of dissolved oxygen decreases, and the cornea does not get enough of the oxygen it needs.
- the decrease in tear volume can be prolonged due to ophthalmological diseases causing tear secretion deficiency, decrease in tear secretion due to aging, etc., decrease in environmental humidity due to inadequate air conditioning, reading 'using a computer', and driving This is due to increased tear evaporation due to gaze and wearing of contact lenses.
- dry eye may indicate a disorder such as corneal conjunctival epithelial disorder or dry eye syndrome caused by a qualitative or quantitative abnormality of tears, or a decrease in tear volume and dryness of the eyes. Show symptoms like feeling There are cases.
- Dry eye associated with wearing contact lenses is due to a marked decrease in tear exchange rate upon blinking and evaporation of water from the lens surface.
- the oxygen permeability without PMMA (polymethylmethacrylate) Material of the lenses, oxygen permeable lenses (RGP lenses, 0 2 lens) to change the lens miniaturized lenses Improvements have been made to promote tear exchange from the rim, but contact lenses that can completely prevent the above problems have not yet been provided.
- Soft contact lenses on the other hand, are usually large enough to cover the entire cornea and very well conform to the shape of the eye, so that the rate of tear exchange from the edge of the lens is hard contact. Oxygen deficiency is more likely to occur than lenses.
- contact lenses affect corneal oxygen deficiency, and long-term wear is particularly likely to cause corneal disorders such as corneal edema and vascular invasion due to lack of oxygen.
- An object of the present invention is to provide an ophthalmic composition that can supply a sufficient amount of oxygen to the cornea and conjunctiva and is useful for the prevention and treatment of eye diseases and symptoms caused by oxygen deficiency. .
- An object of the present invention is to provide an ophthalmic composition that can supply a sufficient amount of oxygen to the cornea and is useful for preventing and treating corneal disorders such as corneal swelling and corneal edema.
- the present invention provides an ophthalmic composition having an increased oxygen content. More specifically, the present invention provides
- the amount of dissolved oxygen and / or oxygen in the oxygen donor is not less than 8.84 mg per liter of the ophthalmic composition at 1 atm and 20 ° C (1) or (2)
- the oxygen donor is an oxygen carrier capturing oxygen.
- the oxygen carrier is a fluorocarbon
- the oxygen carrier is (a) hemoglobin or a polymer thereof, (b) a modified hemoglobin or a polymer thereof, and (c) a porphyrin complex.
- Oxygen-impermeable container, oxygen-impermeable container, oxygen-impermeable envelope or oxygen-impermeable envelope is a group consisting of ethylene-butyl alcohol copolymer, polyethylene naphthalate, and polyethylene terephthalate.
- Fig. 1 shows a rabbit with a PMMA lens infused with physiological saline 10 times every 30 minutes, and after 6 hours, the cornea was removed, stained with HE (hematoxylin-eosin) and stained with an optical microscope. It is a mimic of an optical micrograph showing the result of observation below.
- Fig. 2 shows a heron with a PMMA lens attached to it, similar to Fig. 1.
- FIG. 2 is a mimetic view of an optical micrograph of the egret cornea when a light ophthalmic composition (dissolved oxygen content at 20 ° C. is 40 mg / L) is instilled.
- “increased oxygen content” means that the oxygen content in the composition is positively (artificially) increased. In other words, it means an ophthalmic composition that contains more oxygen than is normally dissolved under the same conditions, ie, an excess of oxygen.
- normal temperature means about 15 to 25 ° C
- normal pressure means about 1 atm.
- the composition of the present invention having an increased oxygen content is also referred to as “oxygen-rich ophthalmic composition” or simply “oxygen-rich composition”.
- the ophthalmic composition of the present invention preferably contains oxygen at 90% or more of the saturated dissolved oxygen concentration in the presence of 1 atm of air, and contains oxygen at a saturated dissolved oxygen concentration of 1 atm or more in the presence of air. Is more preferable. In the air presence of 20 ° C, 1 atm, saturated dissolved oxygen concentration in water is about 8. 84 mg / L, the concentration of oxygen dissolved in the conventional ophthalmic composition from about 5 m g / / L.
- Oxygen donor refers to a substance in which oxygen is captured by an oxygen carrier as defined below.
- Oxygen carrier refers to a compound capable of scavenging and transporting oxygen. It is preferable that such a carrier captures oxygen at a high oxygen partial pressure and releases oxygen at a low oxygen partial pressure.
- any oxygen donor can be used provided that it is ophthalmically acceptable, such as (a) fluorocarbon, (b) hemoglobin or its polymer, (c) modified hemoglobin or A compound having an oxygen-carrying function such as the polymer, (d) a vorphyrin complex or a polymer thereof, or (e) hemoglobin or a polymer thereof, a modified hemoglobin or a polymer thereof, or a lipid vesicle containing a porphyrin complex or a polymer thereof.
- Oxygen-impermeable container means a container that has no oxygen permeability.
- oxygen low permeability container means a container having low oxygen permeability. Examples of such a container include a container formed of a high gas barrier material, a container formed of a high gas barrier material, and a container containing a high gas barrier material.
- a container in which a plastic such as polyethylene and a high gas barrier material are formed in multiple layers may be used as long as the effects of the present invention are not affected.
- oxygen-impermeable envelope refers to, for example, an envelope made of aluminum foil or a high gas barrier material, an envelope made of these materials, An enclosure having a high gas barrier material may be used.
- the enclosure may be a single or multilayer film.
- the envelope is formed by coating a film of a polyvinyl alcohol-based material or a polyamide-based material with a metal oxide such as aluminum or aluminum oxide, or a ceramic such as silicon oxide by vapor deposition, or a polychlorinated film. It may be one coated with vinylidene.
- the enclosure containing the high gas barrier material include, for example, an enclosure in which a plastic such as polyethylene and a high gas barrier material are formed in a multilayer, as long as the effect of the present invention is not affected.
- Oxygen permeable container means a container formed of an oxygen permeable material, which is permeable to oxygen and does not contain a high gas barrier material.
- oxygen-permeable material examples include Teflon, polystyrene, polyethylene, and polypropylene.
- the “high gas barrier material” a material having no oxygen permeability or a material having low oxygen permeability is preferable. Specifically, those having an oxygen permeation amount of 0 to 200 ml / m 2 'day-MPa (measured at a thickness of 20111, 20 ° C, and 65% RH) are preferable, and 0 to 50 O ml / m 2 ⁇ day ⁇ MPa (measured at a thickness of 20 / zm, 20 ° C, 65% RH) is more preferable, and 0 ⁇ 10 Oral / ra 2 ⁇ day ⁇ MPa (thickness 20 / ra, measured at 20 ° C and 65% RH).
- Thermoplastic plastic materials are particularly suitable as the high gas barrier material, and specific examples include polyamide (eg, nylon 610), EV0H (ethylene-vinyl alcohol copolymer), and PVDC (polyvinyl chloride). Den), PEN (polyethylene naphthalate), PET (polyethylene terephthalate) and the like. Among them, EV0H, PET, and PEN are preferable. Further, these materials having improved gas barrier properties may be stretched.
- Preferred containers or envelopes in the present invention include: (1) an oxygen-impermeable container, (2) a low-oxygen-permeability container containing a high gas barrier material, and (3) a combination of an oxygen-permeable container and an oxygen-impermeable envelope or oxygen permeation. It is a combination of a flexible container and a low oxygen permeable enclosure. Low oxygen permeable containers or low oxygen permeable enclosures made of high gas barrier material only, plastics such as polyethylene and high gas barrier material formed in multiple layers, resin mixed with high gas barrier material And the like.
- the oxygen-rich ophthalmic composition of the present invention is not particularly limited as long as it is a dosage form suitable for allowing the contained oxygen to reach the cornea, but is preferably an aqueous preparation, and is preferably an aqueous solution, suspension or suspension. More preferably, it is an emulsion. Particularly, an aqueous solution is preferable.
- the oxygen content in the composition of the present invention containing oxygen and / or an oxygen donor may be about 8.84 mg or more, preferably about 8.84 mg to 225 mg , more preferably about 10 to 220 mg, per liter of the composition. Preferably, it is about 14 mg to 180 mg. Usually, it is preferable that the composition contains 10 mg or more of oxygen per 1 L as a total of dissolved oxygen and oxygen in the oxygen donor.
- the oxygen-rich ophthalmic composition of the present invention contains greater than about 8.84 mg oxygen per liter. More preferably, 1 atm, at 20 ° C, 8. 84 ⁇ 225mg, more preferably 10 ⁇ 220Mg, particularly good Mashiku containing oxygen 14 ⁇ l 8 0mg.
- the oxygen-rich ophthalmic composition of the present invention preferably contains 1.5 times or more oxygen as compared with a normal ophthalmic composition.
- the oxygen rich ophthalmic composition according to the present invention can be prepared by any method used to cause the composition to contain an excess amount of oxygen. Add donor substance or excess oxygen gas It is simply and suitably prepared by a method of dissolving in water. For example, by dissolving oxygen at a low temperature or / and in an atmosphere having a high oxygen partial pressure, it is possible to produce an oxygen-rich ophthalmic composition containing oxygen at a saturated dissolved oxygen concentration or more at normal temperature and normal pressure. it can.
- the oxygen-rich ophthalmic composition according to the present invention is preferably sterilized in any step of the formulation step, for example, using a known sterilization method such as filtration sterilization. After sterilization, it is preferable to produce an oxygen-rich ophthalmic composition under a sterile environment.
- Fluorocarbon is a compound in which part or all of the hydrogen of an organic compound has been replaced with fluorine, has oxygen-carrying ability, and is selected from physiologically acceptable compounds. Fluorocarbon is a physiologically acceptable substance because it can be excreted from the lungs with exhaled breath without being metabolized when absorbed by the body.
- the fluorocarbon usable in the present invention includes the following formula (1):
- n 4.
- perfluoro / leo carbon examples include perfluorocycloalkane, perfluoroalkylcycloalkyl, perfluoroalkane, and the like.
- the number of carbon atoms is preferably from 5 to 20, and more preferably from 9 to 11.
- Perf / leoloanolequinolecycloanolecan may have a heterocyclic ring in place of cycloanolecan, for example, perfluoromethylpropyl cyclohexane, perf / leolobutinolesic mouth Hexane, perfluorotrimethylcyclohexane, I-Fluoroechizoleprovir cyclohexane, perfluoro ⁇ Perfluoro over C 3, such as decalin or perfluoro full O b methyl des forces phosphorus 5 - hexanes Arukirushiku port; Pafuruo port to good of Kishirutetorahi Dorobiran Una perfluoro over C 4 - 6 - alkyl tetra arsenide Doropiran; Pafuruoropen Chirutetorahi Dorofuran, to Pafuruo port Kishirutetorahi Dorofuran be properly perfluoro over
- the third Amin for example, Pafuruoro third Arukirua Min, Pafunoreoro N-C 4 ⁇ 6 - Arukirupi Bae lysine, or a perfluoroalkyl over N one C 5 ⁇ 7 - such as an alkyl morpholine.
- the number of carbon atoms is preferably 3 to 20, and the number of carbon atoms is preferably 9 to 11.
- perfluorinated tertiary alkylamines include, for example, perfluoro- ⁇ , ⁇ -dibutylmonomethylamine, perfluoro ⁇ , ⁇ -ethyl-pentylamine, perfluoro ⁇ , ⁇ _ acetylhexylamine, "-fluoro-, ⁇ -dipropyl
- perfluorophenolic triolenoquinoleamines such as petit / reamine or perfluorotripropylamine
- perfluoromono-, di-dialkylcycloalkylamines such as perphnoleol ⁇ , ⁇ -decylcyclohexylamine.
- the fluorocarbon as the oxygen carrier is preferably used in the form of an emulsion stable in a physiologically acceptable aqueous solvent or an emulsion at the time of use.
- an emulsifier or, if desired, an emulsifying aid and, if desired, a solubilizing agent such as salts, alcohols, propylene glycol, etc., a stabilizer, a buffer, water, or a ⁇ regulator are added to fluorocarbon, for example, distilled water,
- the mixture is added to a physiologically acceptable aqueous solvent such as saline or PBS (phosphate buffered saline) to form an emulsion by a known or equivalent method, and dispersed in an ophthalmic composition.
- a physiologically acceptable aqueous solvent such as saline or PBS (phosphate buffered saline)
- the average particle size of the emulsion is preferably from about 0.05 to about 0.3.
- fluorocarbons and fluorocarbon compounds may be used.
- Commercially available fluorocarbons include Inner Liquid FC-43, FC-75, FC-77, FC-78, FC-88 (Minnesota And a commercially available fluorocarbon emulsion such as Full Ozone> (manufactured by Green Cross Co., Ltd.).
- Liquid fluorocarbons can also be used, and they can be produced by a known method such as the method described in JP-A-02-271907 or a method analogous thereto.
- Sterilization of the ophthalmic composition containing fluorocarbon as an oxygen carrier is preferably performed by a method that does not affect the dispersibility of the fluorocarbon emulsion.
- fluorocarbon may be condensed.
- it is preferable to perform sterilization by a known method for example, a method described in JP-A-48-26912).
- the step of trapping oxygen with the fluocarbon can be performed at any stage of the entire formulation process, but is preferably performed after sterilization, preferably in a sterile environment.
- a known method or a method similar to the method of dissolving oxygen in the fluorocarbon emulsion under an atmosphere having a high oxygen partial pressure or a method of bubbling oxygen gas may be used. it can.
- fluorocarbon has a specific gravity of 1.5 to 2.5, it is preferable to use an ophthalmic composition containing carbon having a phenolic opening when shaking.
- hemoglobin When the oxygen carrier is hemoglobin or a polymer thereof, or a modified hemoglobin or a polymer thereof (hereinafter, referred to as “hemoglobin etc.”).
- the hemoglobin is not particularly limited, and human or animal (particularly, mammals). Can be obtained from erythrocytes or enriched erythrocyte compositions derived from cattle, pigs, etc.) by a known method such as the method described in JP-A-11-046759 or a method analogous thereto.
- Hemoglobin may be a polymer, and the polymer can be produced by a known method or according to a known method.
- modified hemoglobin examples include modified hemoglobin obtained by combining hemoglobin with polyoxyethylene or polyethylene dalicol, Alternatively, modified hemoglobin obtained by using glutaraldehyde or bis (3,5-dibu-mouthosalicyl) fumarate as a cross-linking agent, specifically, modified hemoglobin or heme-conjugated aluminin, which selectively binds the alpha chains of hemoglobin to each other.
- the method of capturing oxygen with hemoglobin or the like is performed by a known method or a method analogous thereto.
- hemoglobin or the like is dissolved in a solvent conventionally used in this field such as physiological saline, PBS or Ringer's solution containing lactic acid, and oxygen is trapped in the hemoglobin or the like by increasing the oxygen partial pressure of the solvent.
- a solvent conventionally used in this field such as physiological saline, PBS or Ringer's solution containing lactic acid
- oxygen is trapped in the hemoglobin or the like by increasing the oxygen partial pressure of the solvent.
- the oxygen partial pressure is adjusted depending on the amount of oxygen to be dissolved in the ophthalmic composition, it is preferably about 40 mmHg to about 150 ramHg.
- Sterilization of an ophthalmic composition containing hemoglobin or the like as an oxygen carrier can be performed by a known method.
- hemoglobin is oxidized to methemoglobin, for example, during the preparation of oxygen-entrapped hemoglobin or during storage before use, the oxygen binding capacity is lost and the oxygen transport capacity is lost .
- the appearance of such a carrier lacking oxygen carrying ability can be suppressed by a known method. Since the oxidation rate of hemoglobin depends on temperature, pH, and the like, the oxidation of hemoglobin and the like can be suppressed by maintaining the temperature at a low temperature and / or at a pH of about 6.5 to 9.0. It is preferable to prepare and store hemoglobin or the like at a low temperature (about 0 ° C. to 4 ° C.) and / or at a constant pH (about 6.5 to 9.0).
- a reducing agent harmless to the human body such as ascorbic acid can also suppress the oxidation of hemoglobin and the like.
- a method of reducing hemoglobin such enzymatically (Biochimicaet Biophysica Acta 310: 309 - 316 N Archives of Biochemistry and Biophysics 77: 478 - 492), a method of reducing the oxidation of hemoglobin and the like by adding a specific alcohol (Biotechnology and Applied
- Biochemistry 18: 25-36 is known, and they may be used.
- protective ligands include gaseous protective ligands such as nitric oxide (N0) or carbon monoxide.
- “Derivatives” include non-gaseous competing ligands such as, for example, nitro compounds and isocyanides.
- the oxygen carrier in the present invention may be one in which the above hemoglobin or the like is encapsulated in lipid vesicles.
- Lipid endoplasmic reticulum is composed of multiple liposomes composed of multiple lipid membranes.
- MLV Multilamellar LiPosome or Vesicle
- SUV Single Compartment Liposome or Small Unilamellar Vesicle
- LUV Large Unilamellar Vesicle
- small ribosomes are preferred.
- the lipid constituting the endoplasmic reticulum may be any lipid as long as it is ophthalmically acceptable, and may be selected from phosphatidylcholine (PC), phosphatidinoreserin (PS), phosphatidinolethananolamine (PE), Phosphatidylinositol (PI), lysophosphatidylcholine (LPC), ganglioside (G), gargiolipin (CL), sphingomyelin (SM), dipalmitoylphosphatidylcholine (DPPC), dimyris toinole phosphatidylcholine (DMPC), distearoylphosphatidylcholine DSPC), phosphatidic acid (PA), or phosphatidylglycerol (PG), or those obtained by subjecting them to hydrogenation according to a conventional method.
- PC phosphatidylcholine
- PS phosphatidinoreserin
- PE phosphatidinolethananolamine
- lipids selected from known substances used in the art, such as cholesterol (CH0L), dicetyl phosphate (DCP), stearylamine (SA), or polyethylene glycol (PEG).
- Cholesterol can be used for ER formation, membrane stabilization, and regulation of ribosome membrane permeability.
- dicetyl phosphate is negatively charged and stearylamine is positively charged, these can be used as charge-imparting substances for regulating the contact between ribosomes and cells.
- Polyethylene glycol can be used to prevent aggregation between ribosomes.
- homologs of tocopherol may be added.
- Tocofurol is a biological component that has a nonspecific antioxidant effect and contributes to the stability of the endoplasmic reticulum membrane or hemoglobin as an antioxidant. In particular, it can be an important component in the endoplasmic reticulum containing unsaturated lipids. Further, in order to suppress the change of hemoglobin or the like into methemoglobin or the like, it is preferable to incorporate a methation inhibitor into the lipid vesicles.
- the methation inhibitor include saccharides constituting an anaerobic glycolysis system and methation suppression precursors. Specifically, malic acid is mentioned as a saccharide constituting the anaerobic glycolysis system.
- met-suppressing precursor examples include substances that remove active enzymes such as cytochrome b5, NADH-cytochrome b5 reductase, NADH-flavin reductase, catalase, superoxide dismutase, and glutathione peroxidase.
- Hemoglobin arosteric factor can also be included in the lipid vesicles.
- the aqueous phase in the endoplasmic reticulum can contain high concentrations of hemoglobin and the like, and as a result, the viscosity and colloid osmotic pressure of the ophthalmic composition can be reduced. There is. Since the lipid vesicles containing purified hemoglobin and the like have a much higher affinity for oxygen than erythrocytes and a very high oxygen-binding ability, it is difficult to release oxygen at low oxygen partial pressures.
- the oxygen transport function oxygen supply capacity
- hemoglobin and other hemoglobin are encapsulated in lipid vesicles together with hemoglobin and the like, thereby reducing the oxygen affinity of hemoglobin and the like under low oxygen partial pressure.
- the ability of the containing lipid vesicles as an oxygen carrier can be improved.
- hemoglobin allosteric factor examples include 2,3-diphosphoglyceric acid, inosit hexanoic acid (IHP), polycarboxylic acid, and condensed phosphoric acid.
- an electrolyte having chlorine ion as an anion and an organic phosphoric acid derivative can also be used.
- electrolytes that use chloride ions as anions include sodium chloride, potassium chloride, calcium chloride, and magnesium chloride
- examples of phosphate derivatives include adenosine triphosphate (ATP) and adenosine diphosphate ( (ADP), or pyridoxal-5-phosphate (PLP).
- equation (2) As an example of the allosteric factor, equation (2):
- each of these compounds (2) and (3) has two asymmetric carbons, there are a plurality of stereoisomers (diastereoisomers and optical isomers).
- the composition of the present invention not only a pure isomer but also a mixture of a compound, a racemate, and a diastereomer in which arbitrary isomers are mixed at an arbitrary ratio can be used.
- the compounds of the formulas (2) and (3) can be used alone or in any combination.
- Physiologically acceptable base addition salts of the compounds of the formulas (2) and (3) include, for example, salts of alkali metals or alkaline earth metals such as sodium, potassium or calcium salts; ammonium salts.
- a salt of an organic base such as a methylamine salt, an ethylamine salt, or a trimethylamine salt.
- the compounds represented by the above formulas (2) and (3) are known, and can be obtained from commercial products, or can be produced by a known method or a method analogous thereto.
- Methods for preparing lipid vesicles are known and are not particularly limited. Although it can be produced according to a conventional method, it is important that hemoglobin and the like are easily oxidized to methemoglobin having no oxygen transport function by temperature, light, hydrogen ion concentration, dissolved gas, or metal ions. Considering this, for example, a glass bead stirring method, a cholic acid removal method, a reverse phase evaporation method, a French press method, a Ca 2+ fusion method, a pearl bombing method, or a dehydration-rehydration method can be used.
- the obtained endoplasmic reticulum is dissolved in a solvent conventionally used in the field, such as physiological saline, PBS or Ringer's solution containing lactic acid, and the oxygen partial pressure of the solvent is increased.
- a solvent conventionally used in the field such as physiological saline, PBS or Ringer's solution containing lactic acid
- oxygen partial pressure of the solvent is increased.
- oxygen is captured by hemoglobin or modified hemoglobin.
- the oxygen partial pressure is appropriately adjusted depending on the amount of oxygen to be dissolved in the ophthalmic composition, it is usually preferably about 40 mmHg to about 150 mmHg.
- the endoplasmic reticulum containing hemoglobin or the like as an oxygen carrier of the composition of the present invention is preferably stored frozen.
- sugar-glycerol is preferably added as a cryoprotectant for long-term stable storage.
- oligoglycolipids in which a long-chain alkyl is ester-linked to an oligosaccharide or glycolipids in which a long-chain alkyl is an ether bond, an amide bond, or an ester bond at the terminal anomeric position of an oligosaccharide chain, are likely to cause aggregation of ERs Since it has a fusion inhibitory effect, it can be cryopreserved by adding a compound selected from these as a stabilizer of the endoplasmic reticulum.
- the porphyrin complex used as an oxygen carrier in the composition of the present invention is obtained by improving the iron (II) porphyrin complex present in hemoglobin or myoglobin in order to improve the stability at room temperature and the like. ):
- R represents hydrogen or a substituent
- M represents a transition metal ion in the fourth to fifth cycles. Or a state in which a hydrogen atom is bonded to a nitrogen atom represented by N 2 or N 4 without a transition metal ion.
- n represents the number of methylene groups and represents an integer of 1 to 20.
- M is preferably a divalent or trivalent iron ion, or divalent cobalt ions.
- M is a divalent iron ion
- X and Y are hydrogen
- R 1 . 5 There is a methyl group, 10, 15, 2 0 tetrakis (a, a, a, shed one o- Pibaruami Dofuweniru) porphyrin iron (II) complexes, axial base, for example 1 one Al kill imidazole or 1 one Alkyl
- 2-methylimidazole and the like coexist, benzene, toluene, or ⁇ , ⁇ -dimethylformamide It can reversibly bond with oxygen molecules at room temperature in organic solvents.
- the composition is included in the lipid vesicles described in the above (B).
- Borufuirin complexes of this type under physiological conditions (aqueous phase system, approximately P H7. 4, about 40 ° C or less) reversible binding ability to even the oxygen (oxygen adsorption-desorption ability), It can function as the oxygen carrier according to the present invention.
- port Rufuirin complexes with phospholipids like structure (4) is when dispersed in water with phospholipid form vesicles bilayer.
- the vorphyrin complex layer is embedded in a state of being uniformly dispersed on the hydrophobic layer side, so that it has the ability to reversibly bind to oxygen adsorption and desorption even in an aqueous medium, and as an oxygen carrier according to the present invention.
- the porphyrin complex having a phospholipid-like structure may be further included in a lipid vesicle. Encapsulation in lipid vesicles makes it possible to stably repeat oxygen absorption and desorption for a long time.
- R one S0 3 H, C 6 ⁇ 2 .
- R 'or R represents a linear aliphatic hydrocarbon group. It is preferable that R' has 1 to 10 carbon atoms and R" has 1 to 20 carbon atoms. And may be the same or different.
- the chain aliphatic hydrocarbon group may be linear or branched, and may be saturated or unsaturated.
- R is preferably a straight-chain aliphatic hydrocarbon group having 1 to 18 carbon atoms.
- the chain-like aliphatic hydrocarbon group may be substituted by halogen. There is no particular limitation as long as it is chemically acceptable.
- the "C 6 ⁇ 2. Of Ariru group” has a carbon number of 6 to 20 aromatic hydrocarbon group may be partially saturated.
- aromatic hydrocarbon group may be partially saturated.
- phenyl, benzyl, biphenyl, indenyl, naphthyl, or a partially saturated form thereof such as 2,3-dihydroindull or 1,2,3,4-tetrahydronaphthyl, etc. I can do it.
- the imidazole derivative as a substituent has the general formula (6):
- R 1 is one 0C0NH-, represents an C0NH- or single NHC0- alkylene group having 2 to may be interrupted.
- R 2, R 3 or R 4 is respectively the same or different Represents hydrogen or an alkyl group of ⁇ 6 .
- the imidazole derivative can be added to the composition as an axis base independently of the vorphyrin complex. If the imidazole derivative is present in an excessive amount, it may have its own pharmacological action or toxicity, and if it is encapsulated in lipid vesicles, it may destabilize the morphology of the lipid vesicle There is a possibility that it becomes. Therefore, by introducing the imidazole derivative by a covalent bond into the molecule as a substituent, the amount of the axial base added can be minimized. An appropriate substituent can be introduced at the 2-position of the porphyrin ring to enable covalent bonding with a highly lipophilic substance.
- an ester or amide bond with a fatty acid increases the lipophilicity of the vorphyrin complex, so that the vorphyrin complex is easily dissolved in the hydrophobic region of the lipid vesicle and easily included in the lipid vesicle.
- porphyrin complex represented by the formula (4) when M is ten divalent metal, Usually, two hydrogens are coordinate-bonded as X and Y, but by replacing one or both of these ligands with an imidazole derivative, the amount of axial base added can be minimized. There are advantages such as being able to.
- an imidazole derivative as a ligand is bonded to a transition metal ion M at the center of the porphyrin ring in the formula (4) by an ester bond at a ratio of 1 mol to 1 mol of the porphyrin, and a formula ( 7 ):
- m represents an integer of 7 to 17
- R 5 represents hydrogen or a methyl group
- M and R 10 are the same as defined above.
- a porphine complex represented by This complex has the advantage that the addition amount of the axial base can be minimized.
- the porphyrin complex having a bulky substituent on only one side of the ring forms a dioxo duplex and is oxidized to an iron (II) porphyrin complex having no oxygen binding ability. Is not preferred.
- porphyrin complex represented by the formulas (7) and (8) can be included in the lipid vesicle.
- the porphyrin complex used as the oxygen carrier in the present invention can be produced by a known method, for example, a method described in JP-A-59-162924.
- porphyrin complex used as the oxygen carrier according to the present invention examples include, in addition to the vorphyrin complex represented by the above (4), (7) or ( 8 ), iron (II) porphyrin complex present in hemoglobin / miodarobin. Similar oxygen absorption / desorption function Known synthetic iron (II) porphyrin complex (JP Collraan, Accountsof
- the oxygen carrier according to the present invention may be a polymer of the above porphyrin complex.
- the polymer can be produced by polymerizing a vorphyrin complex by a known method or a method analogous thereto.
- the emulsion or solution containing the oxygen-donating substance thus produced may be used as it is as the ophthalmic composition of the present invention, but may be further sterilized if necessary, or may be distilled water or physiological saline. Or the like, or the following components may be further added.
- the oxygen-rich ophthalmic composition of the present invention can be produced without using an oxygen donor by increasing the concentration of dissolved oxygen.
- a method in which oxygen is included in an ophthalmic composition under an oxygen gas atmosphere specifically, a method of bubbling oxygen into the composition, and a method of ophthalmic composition under a high-pressure oxygen gas atmosphere.
- the high pressure means about 1.2 to 5 atm.
- the oxygen-rich ophthalmic composition of the present invention can also be produced under low-temperature conditions.
- the temperature is preferably about 0 ° C to 5 ° C.
- the above method may be performed at a low temperature. That is, a method in which oxygen is directly bubbled into the ophthalmic composition under a low-temperature oxygen gas atmosphere, or a method in which oxygen is dissolved in the ophthalmic composition under a high-pressure oxygen gas atmosphere at a low temperature.
- the obtained composition is subjected to a sterilization treatment such as sterilization filtration, if desired.
- the sterilization may be performed in an air atmosphere or an oxygen atmosphere, but the latter is preferable because the reduction of dissolved oxygen is suppressed.
- composition containing an excessive amount of dissolved oxygen obtained by the method (1) or (2) is finally filled in an oxygen-permeable container, and this is filled with an oxygen-impermeable envelope or
- an oxygen-permeable container By enclosing with a low oxygen permeable enclosure and replacing the space formed between the container and the enclosure with oxygen gas and sealing, the amount of dissolved oxygen at the time of preparation is maintained substantially constant. It is possible to obtain an oxygen-rich ophthalmic composition which is optionally increased.
- the oxygen-rich ophthalmic composition of the present invention may contain any component that is generally contained in ophthalmic compositions provided that it does not adversely affect the oxygen content.
- ophthalmic compositions provided that it does not adversely affect the oxygen content.
- inorganic salts, saccharides, vitamins, amino acids, epidermal growth factor, active oxygen scavenger, tissue activator or metabolism promoter, corneal epithelial layer disorder treatment or corneal epithelial layer extension promoter, coenzyme, or cell differentiation promotion Agents can be included in proportions commonly used in the art.
- inorganic salts examples include potassium chloride, calcium chloride, sodium chloride, sodium hydrogen carbonate, sodium carbonate, magnesium sulfate, sodium hydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate.
- saccharide examples include a monosaccharide such as glucose, a disaccharide such as sucrose, and a polysaccharide such as dextran, cyclodextrin or hyaluronic acid.
- vitamins include nicotinic acid, nicotinamide dinucleotide
- NAD flavinamide dinucleotide
- vitamins D preferably vitamin D3
- vitamin B2 vitamin B6, vitamin B12, panthenole, calcium pantothenate, sodium pantothenate, vitamin A acetate, vitamin E Acetate or retinol palmitate.
- Amino acids include, for example, aspartic acid, L-aspartic acid M g ⁇ K,
- Aspartic acid and its salts such as L-aspartic acid or L-aspartic acid Mg; and chondroitin sulfate sodium.
- epidermal growth factor examples include taurine (aminoethylsulfonic acid).
- Active oxygen scavengers include, for example, SOD or SOD-like active substances. I can do it.
- Tissue activators or metabolic promoters include aspartic acid and its salts.
- Examples of the therapeutic agent for corneal epithelial layer disorder or the agent for promoting corneal epithelial layer extension include hyaluronic acid which is a polysaccharide and glucose which is an energy source of a living body.
- coenzymes include vitamins such as NAD and FAD.
- examples of the cell differentiation promoter include vitamin Ds (preferably vitamin D3).
- those preferably added to the oxygen-rich ophthalmic composition of the present invention are inorganic salts, saccharides, vitamins, amino acids, epidermal growth factor and active oxygen scavenger, and particularly preferred components are glucose, Hyaluronic acid, nicotinamide dinucleotide (NAD), flavinamide dinucleotide (FAD), vitamins D, aspartic acid and its salts, taurine, SOD or SOD-like active substance.
- the ophthalmic composition of the present invention may contain other components used in ordinary ophthalmic compositions in usual use amounts.
- the following components may be contained as needed.
- a decongestant component such as, for example, epinephrine, epinephrine hydrochloride, ephedrine hydrochloride, tetrahydrozoline hydrochloride, naphazoline hydrochloride, naphazoline sulfate, fuerefrin hydrochloride or methylefedrin hydrochloride.
- Anti-inflammatory agents such as dipotassium glycyrrhizinate, epsilon aminocaproic acid, allantoin, berberine chloride, berberine sulfate, sodium azulene sulfonate, zinc sulfate, zinc lactate, or lysozyme chloride.
- Antihistamines such as, for example, diphenhydramine hydrochloride or chlorpheniramine maleate.
- Quaternary ammonium salt-type preservatives such as benzalkonium chloride or benzethonium chloride; chlorhexidine hydrochloride, chlorhexidine dalconate, dodecylguanidine hydrochloride, or 6-acetoxy 2,4-dimethyl Guanidine preservatives such as metadioxane or preservatives such as butanol.
- Viscosity agents such as, for example, polyvinyl alcohol, polyvinylpyrrolidone, hydroxyethynoresenorelose, hydroxypropyl / methinoresenololose or methinoresenolle mouth.
- a buffer such as boric acid.
- a PH regulator such as borax.
- Dissolution aids such as polyoxyethylene hydrogenated castor oil.
- the ophthalmic composition according to the present invention is preferably prepared so that the pH is about 4 to 9.
- the pH is preferably maintained at about 6.5 to 9.0 in order to suppress oxidation.
- the oxygen-rich composition of the present invention can maintain a high oxygen content in a closed container, it reliably and stably supplies oxygen to the cornea for a long period (typically, about one to three years).
- the oxygen-permeable container may be filled with an oxygen-rich ophthalmic composition and further enclosed and sealed with an oxygen-impermeable or oxygen-impermeable envelope as defined above. By doing so, the maintenance of the effective oxygen concentration becomes more certain.
- the container when the container is filled with the oxygen-rich ophthalmic composition, it is preferable to replace the voids in the filled container with oxygen or to fill the container so that the porosity of the container is 10% or less.
- an oxygen-permeable container containing an oxygen-rich ophthalmic composition or an ophthalmic composition prepared according to a conventional method is surrounded by an oxygen-impermeable envelope or a low-oxygen-permeability envelope, and sealed.
- an oxygen-rich ophthalmic composition can be easily formed. Can be manufactured and stored safely. That is, when the oxygen in the enclosure penetrates into the oxygen-permeable container, the oxygen partial pressure in the space of the container increases, and the amount of dissolved oxygen in the composition increases. It is also advantageous in that the reduction of dissolved oxygen in the composition is prevented.
- the amount of oxygen to be filled in the space between the oxygen-permeable container and the oxygen-impermeable or low-oxygen-permeability enclosure is determined in a closed environment, between the oxygen atmosphere in the space and the dissolved oxygen in the ophthalmic composition. Sufficient to maintain the desired equilibrium. Preferably, about 50% or more of the space volume is replaced with oxygen gas. As described above, since an equilibrium state is achieved between the oxygen atmosphere in the space around the container and the dissolved oxygen of the ophthalmic composition, the dissolved oxygen amount is maintained for a long period of time.
- the ophthalmic composition according to the present invention includes, for example, (1) a step of filling an ophthalmic composition containing an oxygen carrier or a normal ophthalmic composition into a container, (2) A step of allowing the ophthalmic composition to contain oxygen, (3) a step of sealing the container and surrounding it with an oxygen-impermeable envelope or an oxygen-impermeable envelope, and (4) the step of sealing the container and the envelope. It is manufactured by filling the space with oxygen and sealing it.
- a step of adding oxygen to a normal ophthalmic composition (2) a method of filling the container with the oxygen-rich ophthalmic composition produced in (.1), (3) It is sealed and sealed with an oxygen-impermeable 1 "raw enclosure or an oxygen-impermeable enclosure. (4) It is manufactured by filling the space between the container and the enclosure with oxygen and sealing.
- the step of sterilizing the ophthalmic composition may be provided before or after any of the steps (1) to (4), but in the former method, before and after the step (2).
- the oxygen-rich composition in an oxygen-impermeable container or a low-oxygen-permeable container.
- the shape and size of the container containing the composition are not particularly limited, but are generally rectangular or cylindrical, and the content is generally in the range of about 0.2 mL to about 30 mL. It is preferable to use such a container also in the present invention.
- a blow-filled container is preferable because of its high sealing property.
- a blow-fill seal container containing a high gas barrier material is preferable because an oxygen-rich ophthalmic composition can be stably stored for a long period of time.
- the shape, size, etc. of the enclosure are not particularly limited on the premise that the above-mentioned container can be accommodated.
- the shape and size should be such that after the container is accommodated in the enclosure, a sufficient space for enclosing oxygen can be formed between the container and the container.
- the size is preferably about 1.2 to 2 times the volume of the plastic container.
- the oxygen-rich composition according to the present invention preferably encloses each container containing a unit dose in an enclosure.
- the steps up to filling the container and the step of filling the container are performed at a low temperature or in an oxygen gas atmosphere. After sterilization, it is preferable to fill the containers in an aseptic environment.
- the ophthalmic composition according to the present invention is used, for example, as an eye drop, an eye wash, or a wearing agent for a contagrain.
- a contact lens such as a hard contact lens or a soft contact lens, or at any time during wearing. it can.
- the oxygen-rich ophthalmic composition of the present invention may be used for an ocular disease associated with hypoxia, for example, a punctate disorder such as punctate surface keratopathy, or corneal neovascularization, corneal epithelial erosion or acute corneal epithelial edema, etc. It is useful for preventing or treating corneal epithelial disorder such as planar corneal epithelial disorder and corneal infiltration or corneal endothelial disorder.
- the compositions of the present invention are effective for the above diseases regardless of their cause, but are especially useful for the prevention or treatment of ophthalmic diseases associated with dry eye in contact lens users and computer users. Conceivable. It can also be used to assist tears.
- Example 1 Eye drops
- Sodium edetate was gradually dissolved in 80 ml of water. Boric acid and borax were dissolved in the sodium edetate solution. Next, sodium chloride and potassium chloride were dissolved in the solution. Subsequently, sorbic acid was added and dissolved, and ⁇ was adjusted to about 7.4 with a 0.1N aqueous solution of sodium hydroxide and hydrochloric acid to make the total amount 100 ml. Thereafter, oxygen publishing was performed for 30 minutes at a latm at 20 ° C. in an oxygen gas atmosphere to blow oxygen into the solution to supersaturate the dissolved oxygen amount.
- the mixture was filtered using a cellulose acetate filter having a pore size of 0.2 im in an oxygen gas atmosphere, filled in a sterilized plastic container (made of polyethylene naphthalate), and oxygen was replaced in the void portion with a polypropylene cap.
- the container is sealed, and further covered with an envelope of a composite film mainly composed of polyvinylidene chloride, the space of the container and the envelope is replaced with oxygen, heat-sealed and hermetically sealed. Obtained.
- the dissolved oxygen amount at 20 ° C was 40ing / L, which was about 4.5 times the saturated dissolved oxygen amount.
- Example 2 Eye drops
- a solution was prepared using the same components and method as in Example 1. Under an oxygen gas atmosphere, oxygen bubbling was performed for 30 minutes at a latm at 20 ° C. to blow oxygen into the solution to make the dissolved oxygen amount supersaturated. Furthermore, the mixture was filtered using a cellulose acetate filter with a pore size of 0.2 ⁇ under an air atmosphere, filled in a sterilized plastic container (made of polyethylene naphthalate), and then oxygen-purged in the voids to make a polypropylene packing. An eye drop according to the present invention was obtained by sealing with a screw cap made of aluminum. The dissolved oxygen content at 20 ° C was 9 mg / L.
- a solution was prepared using the same components and method as in Example 1. In a latm at 5 ° C under an oxygen gas atmosphere, oxygen was bubbled through the solution for 30 minutes to supersaturate the dissolved oxygen amount. The solution was filtered through a cellulose acetate filter having a pore size of 0.2 / zm, filled in a sterilized plastic container (made of polyethylene terephthalate), and then sealed with a heat seal to obtain an eye drop according to the present invention. The dissolved oxygen content at 5 ° C was 10 rag / L.
- a solution was prepared using the same components and method as in Example 1.
- Oxygen publishing was performed by blowing oxygen into the solution at 5 atm and 5 ° C under an oxygen gas atmosphere for 30 minutes to supersaturate the dissolved oxygen amount.
- the solution was filtered using a cellulose acetate filter having a pore size of 0.2 m at 5 ° C under an oxygen gas atmosphere, and filled in a sterilized plastic container (manufactured by EV0H). Was obtained.
- the dissolved oxygen content was 180 mg / L at 20 ° C, which was about 20 times the saturated dissolved oxygen content. .
- sodium edetate was gradually dissolved in 20 ml of water.
- l. Og of boric acid and 0.2 g of borax were dissolved.
- 0.7 g of sodium chloride and 0.1 g of chlorinated water were dissolved in the solution.
- 0.1 g of sorbic acid was added and dissolved, and the pH was adjusted to about 7.4 with 0.1N aqueous sodium hydroxide solution and 0.1N hydrochloric acid.
- This solution was added to the above crude emulsion, and the pH was adjusted to about 7.4 with a 0.1N aqueous sodium hydroxide solution and 0.1N hydrochloric acid. Then, add distilled water to make the total volume 100 ml. I got it.
- This solution was emulsified by circulating for 5 minutes under a pressure of 450 atm using a high-pressure emulsifier (Manton-Gaurin emulsifier). Subsequently, oxygen bubbling is performed by bubbling oxygen into the solution at a temperature of 20 ° C. under a pressure of latm, and an inert liquid FC-75 (Minnesota Mining 'and' Manufacturing) Oxygen was captured.
- FC-75 Minnesota Mining 'and' Manufacturing
- the amount of oxygen captured was 15 mg / L.
- the solution is filtered using a cellulose acetate filter with a pore size of 0.2 ⁇ , filled in a sterilized plastic container (made of polyethylene naphthalate), and then surrounded with a composite film mainly composed of polyvinylidene chloride. After coating, the space in the container and the enclosure was replaced with oxygen, and the container was heat-sealed and sealed to obtain an eye drop according to the present invention.
- a white rabbit was fitted with a contact lens made of PMMA (polymethylmethacrylate), which was adapted to the heron's cornea.
- the eye drops prepared in Examples 1 to 3 were instilled 10 times every 30 minutes, and 5 hours later, the cornea was excised to prepare sections. The section was subjected to HE staining (hematoxylin-eosin staining) and observed under an optical microscope.
- the ophthalmic composition according to the present invention is effective for corneal oxygen deficiency and can prevent, alleviate or treat corneal disorders caused by oxygen deficiency.
- Test Example 2 Storage test of oxygen-containing ophthalmic composition
- a container made of polyethylene terephthalate (PET), a container made of polyethylene (PE), a container made of polyethylene naphthalate (PEN), and a container made of ethylene / butyl alcohol polymer (EV0H) were used.
- a DO meter B505 manufactured by Iijima Electronics Co., Ltd. was used.
- the amount of dissolved oxygen decreased after 1 to 2 days after filling, but the amount of dissolved oxygen became constant after that and remained at 20 ° C after 30 days
- the concentration was almost twice as high as the saturated dissolved oxygen content (8.84 tng / L).
- the dissolved oxygen content at 20 ° C was less than 7 days later.
- the dissolved oxygen content is almost the same as after filling after 30 days, and is approximately 2% of the saturated dissolved oxygen content at 20 ° C (8.84 mg / L). The concentration was almost doubled. On the other hand, in the case of the PE container, the dissolved oxygen content at 20 ° C was less than 15 days later.
- the protective effect against corneal swelling caused by eyelid closure was examined using the focus adjustment function as an indicator.
- the test was performed on 10 healthy volunteers. Put 5 ml of the test solution into the eyewash cup, wash both eyes for 10 seconds, and close the eyelids. After 15 minutes, open both eyes and compare the state of focus adjustment with that before instillation according to the above criteria. After the comparison, close the eyelids. 30 minutes after instillation, open both eyes and compare the state of focus adjustment with that before instillation according to the above criteria. After an interval of 6 hours or more, the test was similarly performed on the control solution.
- Test solution 3 L of physiological saline was cooled to 4 ° C, compressed oxygen was bubbled for 30 minutes, and this was filled into a polyethylene terephthalate container (100 ml capacity) to obtain a test solution.
- Dissolved oxygen amount before test 19.5mg / L
- Control solution A saline solution was prepared by filling a polyethylene terephthalate container (100 ml capacity). Dissolved oxygen content before test: 5.4mg / L
- the oxygen-rich ophthalmic composition of the present invention can prevent, alleviate or treat the present invention for a disorder or disease caused by a lack of oxygen in the cornea. Do not attach contact lenses, especially soft contact lenses, It is possible to effectively prevent or treat diseases related to corneal oxygen deficiency typified by dry eye and the like.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001267851A AU2001267851A1 (en) | 2000-06-29 | 2001-06-28 | Oxygen-containing ophthalmic composition |
EP01945653A EP1295602A1 (en) | 2000-06-29 | 2001-06-28 | Oxygen-containing ophthalmic composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000195804 | 2000-06-29 | ||
JP2000-195804 | 2000-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002000228A1 true WO2002000228A1 (fr) | 2002-01-03 |
Family
ID=18694404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/005542 WO2002000228A1 (fr) | 2000-06-29 | 2001-06-28 | Composition ophtalmique contenant de l'oxygene |
Country Status (5)
Country | Link |
---|---|
US (1) | US20020164379A1 (ja) |
EP (1) | EP1295602A1 (ja) |
CN (1) | CN1383383A (ja) |
AU (1) | AU2001267851A1 (ja) |
WO (1) | WO2002000228A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006020657A (ja) * | 2004-07-05 | 2006-01-26 | Otsuka Pharmaceut Factory Inc | 微量元素配合輸液製剤 |
JP2009545001A (ja) * | 2006-07-21 | 2009-12-17 | 株式会社メニコン | 基材を使用した使い捨てソフトコンタクトレンズ用デュオパッケージ |
JP2014015455A (ja) * | 2012-06-14 | 2014-01-30 | Takaaki Matsumoto | 点眼液および点眼液の製造方法 |
CN106176806A (zh) * | 2016-08-29 | 2016-12-07 | 安徽艾珂尔制药有限公司 | 一种硫酸卡那霉素滴眼液及其制备方法 |
JP2019533704A (ja) * | 2016-07-22 | 2019-11-21 | ティシュー テスティング テクノロジーズ エルエルシーTissue Testing Technologies Llc | 糖脂質による細胞凍結保存性の向上 |
KR20210071921A (ko) * | 2019-07-18 | 2021-06-16 | 윤영선 | 산소가 도입된 점안제, 및 그 제조방법 |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7128278B2 (en) | 1997-10-24 | 2006-10-31 | Microdiffusion, Inc. | System and method for irritating with aerated water |
US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
US6386751B1 (en) | 1997-10-24 | 2002-05-14 | Diffusion Dynamics, Inc. | Diffuser/emulsifier |
US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
US7357937B2 (en) * | 2002-09-24 | 2008-04-15 | Therox, Inc. | Perfluorocarbon emulsions with non-fluorinated surfactants |
US7811601B2 (en) * | 2003-04-03 | 2010-10-12 | Seed Co., Ltd. | Ophthalmic lenses capable of sustained drug release and preservative solutions therefor |
US20050008687A1 (en) * | 2003-07-07 | 2005-01-13 | Makoto Yuasa | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same |
WO2005032480A2 (en) * | 2003-10-03 | 2005-04-14 | Judith Boston | Methods, compositions,, apparatuses containing tetrameric oxygen |
CN1942184A (zh) * | 2004-03-04 | 2007-04-04 | 汤浅真 | 包埋有金属卟啉络合物的类脂质体、其制造方法以及利用该类脂质体的药物 |
US20050244512A1 (en) * | 2004-05-01 | 2005-11-03 | Holekamp Nancy M | Ophthalmic fluid and method of delivering same |
US20070297990A1 (en) * | 2006-06-27 | 2007-12-27 | Shah Mandar V | Self-preserving composition |
US20080057023A1 (en) * | 2006-08-29 | 2008-03-06 | Chynn Emil W | Oxygenated ophthalmic composition |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
EP2083876A4 (en) | 2006-10-25 | 2012-09-19 | Revalesio Corp | WOUND CARE AND TREATMENT METHOD |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
CA2667791A1 (en) | 2006-10-25 | 2008-05-02 | Revalesio Corporation | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
CA2667634C (en) | 2006-10-25 | 2016-07-12 | Revalesio Corporation | Mixing device and output fluids of same |
EP1992339A1 (en) * | 2007-05-18 | 2008-11-19 | Saeed Sarkar | Use of a magnesium isotope for treating hypoxia and a medicament comprising the same |
US20080317876A1 (en) * | 2007-05-18 | 2008-12-25 | Saeed Sarkar | Use of a magnesium isotope for treating hypoxia and a medicament comprising the same |
US8202272B2 (en) | 2007-07-19 | 2012-06-19 | Avedro, Inc. | Eye therapy system |
US8992516B2 (en) | 2007-07-19 | 2015-03-31 | Avedro, Inc. | Eye therapy system |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
EP2227197A4 (en) | 2007-12-05 | 2011-06-22 | Avedro Inc | EYE THERAPY SYSTEM |
US8348935B2 (en) | 2008-01-23 | 2013-01-08 | Avedro, Inc. | System and method for reshaping an eye feature |
US8409189B2 (en) * | 2008-01-23 | 2013-04-02 | Avedro, Inc. | System and method for reshaping an eye feature |
US8469952B2 (en) * | 2008-01-23 | 2013-06-25 | Avedro, Inc. | System and method for positioning an eye therapy device |
JP5901291B2 (ja) | 2008-05-01 | 2016-04-06 | リバルシオ コーポレイション | 消化器障害を治療するための組成物および方法 |
JP2012502763A (ja) * | 2008-09-19 | 2012-02-02 | アヴェドロ・インコーポレーテッド | 眼療法システム |
US8366689B2 (en) | 2008-09-30 | 2013-02-05 | Avedro, Inc. | Method for making structural changes in corneal fibrils |
JP2012504472A (ja) | 2008-10-01 | 2012-02-23 | アヴェドロ・インコーポレーテッド | 眼治療システム |
US8882757B2 (en) | 2008-11-11 | 2014-11-11 | Avedro, Inc. | Eye therapy system |
WO2010115121A1 (en) | 2009-04-02 | 2010-10-07 | Avedro, Inc. | Eye therapy system |
WO2010115126A1 (en) * | 2009-04-02 | 2010-10-07 | Avedro, Inc. | Eye therapy system |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
WO2011050164A1 (en) | 2009-10-21 | 2011-04-28 | Avedro, Inc. | Eye therapy |
US8177778B2 (en) * | 2009-10-30 | 2012-05-15 | Avedro, Inc. | System and method for stabilizing corneal tissue after treatment |
US20110237999A1 (en) | 2010-03-19 | 2011-09-29 | Avedro Inc. | Systems and methods for applying and monitoring eye therapy |
BR112012028540A2 (pt) | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
US9492404B2 (en) | 2010-08-12 | 2016-11-15 | Revalesio Corporation | Compositions and methods for treatment of taupathy |
US9044308B2 (en) | 2011-05-24 | 2015-06-02 | Avedro, Inc. | Systems and methods for reshaping an eye feature |
WO2012167260A2 (en) | 2011-06-02 | 2012-12-06 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
WO2013059837A2 (en) | 2012-07-16 | 2013-04-25 | Avedro, Inc. | Systems and methods for corneal cross-linking with pulsed light |
CN102973594B (zh) * | 2012-12-19 | 2016-01-20 | 李洪江 | 一种含有氧气微囊的眼用制剂及制备方法 |
US9498122B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
US9498114B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
KR102545628B1 (ko) | 2014-10-27 | 2023-06-20 | 아베드로 인코퍼레이티드 | 눈의 교차-결합 처리를 위한 시스템 및 방법 |
US10114205B2 (en) | 2014-11-13 | 2018-10-30 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
EP3285704B1 (en) | 2015-04-24 | 2020-11-18 | Avedro Inc. | Systems for photoactivating a photosensitizer applied to an eye |
US10028657B2 (en) | 2015-05-22 | 2018-07-24 | Avedro, Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
US11207410B2 (en) | 2015-07-21 | 2021-12-28 | Avedro, Inc. | Systems and methods for treatments of an eye with a photosensitizer |
CN106265675A (zh) * | 2016-08-29 | 2017-01-04 | 安徽艾珂尔制药有限公司 | 一种抗菌型阿昔洛韦滴眼液及其制备方法 |
JP7387597B2 (ja) | 2017-07-18 | 2023-11-28 | ヴァーテック・バイオ・インコーポレイテッド | ヘモグロビンを含む代用血液及び作製方法 |
EP3761928A1 (en) | 2018-03-08 | 2021-01-13 | Avedro, Inc. | Micro-devices for treatment of an eye |
US10561682B1 (en) * | 2019-04-01 | 2020-02-18 | Judith Boston | Treatment of ischemic conditions, hypoxic conditions, conditions related to a hypoxia-induction factor, or conditions related to reactive oxygen species with oxygen-containing liquids |
WO2020206013A1 (en) * | 2019-04-01 | 2020-10-08 | Judith Boston | Treatment of ischemic conditions, hypoxic conditions, conditions related to a hypoxia-induction factor |
CA3147045A1 (en) | 2019-08-06 | 2021-02-11 | Desmond C. Adler | Photoactivation systems and methods for corneal cross-linking treatments |
US11754753B2 (en) | 2020-04-27 | 2023-09-12 | Coopervision International Limited | Antioxidant contact lens |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0089815A1 (en) * | 1982-03-19 | 1983-09-28 | Sterling Joel Haidt | Liquid perfluorocarbons, for use in ocular therapy, and preparations containing them |
EP0254413A2 (en) * | 1986-06-13 | 1988-01-27 | Yoshiaki Matsuo | Silver-ionic water and its uses |
WO1996003426A1 (en) * | 1994-07-22 | 1996-02-08 | Duke University | Human serum albumin-porphyrin complexes with the ability to bind oxygen and therapeutic uses thereof |
JP2000175595A (ja) * | 1998-12-18 | 2000-06-27 | ▲高▼梨 直治 | 活魚輸送方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389383A (en) * | 1993-06-18 | 1995-02-14 | Allergan, Inc. | Method for treating hypoxia-associated ocular complications |
JP3060133U (ja) * | 1997-10-27 | 1999-07-30 | 株式会社大塚製薬工場 | 眼灌流・洗浄液バッグ包装体 |
FR2776540B1 (fr) * | 1998-03-27 | 2000-06-02 | Sidel Sa | Recipient en matiere a effet barriere et procede et appareil pour sa fabrication |
-
2001
- 2001-06-28 AU AU2001267851A patent/AU2001267851A1/en not_active Abandoned
- 2001-06-28 CN CN01801847.5A patent/CN1383383A/zh active Pending
- 2001-06-28 EP EP01945653A patent/EP1295602A1/en not_active Withdrawn
- 2001-06-28 US US10/070,010 patent/US20020164379A1/en not_active Abandoned
- 2001-06-28 WO PCT/JP2001/005542 patent/WO2002000228A1/ja not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0089815A1 (en) * | 1982-03-19 | 1983-09-28 | Sterling Joel Haidt | Liquid perfluorocarbons, for use in ocular therapy, and preparations containing them |
EP0254413A2 (en) * | 1986-06-13 | 1988-01-27 | Yoshiaki Matsuo | Silver-ionic water and its uses |
WO1996003426A1 (en) * | 1994-07-22 | 1996-02-08 | Duke University | Human serum albumin-porphyrin complexes with the ability to bind oxygen and therapeutic uses thereof |
JP2000175595A (ja) * | 1998-12-18 | 2000-06-27 | ▲高▼梨 直治 | 活魚輸送方法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006020657A (ja) * | 2004-07-05 | 2006-01-26 | Otsuka Pharmaceut Factory Inc | 微量元素配合輸液製剤 |
JP2009545001A (ja) * | 2006-07-21 | 2009-12-17 | 株式会社メニコン | 基材を使用した使い捨てソフトコンタクトレンズ用デュオパッケージ |
JP2014015455A (ja) * | 2012-06-14 | 2014-01-30 | Takaaki Matsumoto | 点眼液および点眼液の製造方法 |
JP2019533704A (ja) * | 2016-07-22 | 2019-11-21 | ティシュー テスティング テクノロジーズ エルエルシーTissue Testing Technologies Llc | 糖脂質による細胞凍結保存性の向上 |
CN106176806A (zh) * | 2016-08-29 | 2016-12-07 | 安徽艾珂尔制药有限公司 | 一种硫酸卡那霉素滴眼液及其制备方法 |
KR20210071921A (ko) * | 2019-07-18 | 2021-06-16 | 윤영선 | 산소가 도입된 점안제, 및 그 제조방법 |
KR102278624B1 (ko) | 2019-07-18 | 2021-07-15 | 윤영선 | 산소가 도입된 점안제, 및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
EP1295602A1 (en) | 2003-03-26 |
US20020164379A1 (en) | 2002-11-07 |
CN1383383A (zh) | 2002-12-04 |
AU2001267851A1 (en) | 2002-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002000228A1 (fr) | Composition ophtalmique contenant de l'oxygene | |
EP1466649B1 (en) | Pharmaceutical composition containing artificial oxygen carrier | |
CA2749698C (en) | Resuscitation fluid | |
CA1289072C (en) | Scaled-up production of liposome-encapsulated hemoglobin | |
CA1202867A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
KR101623993B1 (ko) | 소생액 | |
FR2928270A1 (fr) | Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os | |
US8618056B2 (en) | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries | |
EP1958963B1 (en) | Oxygen-carrying blood substitute preparations | |
Keipert et al. | Effects of partial and total isovolemic exchange transfusion in fully conscious rats using pyridoxylated polyhemoglobin solution as a colloidal oxygen-delivering blood replacement fluid | |
EP0562188B1 (en) | Composition for tissues to sustain viability and biological functions in surgery and storage | |
JP3466516B2 (ja) | 安定保存可能な酸素輸液剤 | |
JP5020525B2 (ja) | 配位子置換型輸液製剤 | |
EP0687463B1 (en) | Hemoglobin-encapsulated liposome | |
KR102278624B1 (ko) | 산소가 도입된 점안제, 및 그 제조방법 | |
US20220313792A1 (en) | Hemoglobin-based nanoparticles for oxygen delivery | |
EP1538151A1 (en) | Artificial oxygen carrier and production method thereof | |
Feriani et al. | Solutions for peritoneal dialysis | |
CN103040744B (zh) | 一种棓丙酯脂质体注射剂 | |
JPH075477B2 (ja) | ヘモグロビン含有リポソームおよびその製法 | |
JPH0374323A (ja) | リポソームの保存方法 | |
Gregory | Liposome-Encapsulated Hemoglobin as an Artificial Oxygen Carrier | |
JP2004059589A (ja) | 安定保存可能な酸素輸液剤 | |
JP2021073301A (ja) | 脂質粒子組成物および医薬組成物 | |
Takeoka et al. | Evaluation of the Oxygen Transporting Capability of Hemoglobin Vesicles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10070010 Country of ref document: US Ref document number: 018018475 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001945653 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001945653 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001945653 Country of ref document: EP |